Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | GRM5 | P41594 | 15/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4055656 | 0.89 | EPHX2 (0.34) | APPGRM5 | |
| SCHEMBL2187490 | 0.88 | APP (0.36) | APPMAPTGRM5KCNH2 | |
| SCHEMBL2763104 | 0.86 | APP (0.32) | APPMAPT | |
| SCHEMBL2189042 | 0.85 | CYP1A1 (0.35) | — | |
| SCHEMBL4059740 | 0.84 | PNMT (0.38) | — | |
| SCHEMBL2763858 | 0.83 | APP (0.38) | APPMAPTGRM5KCNH2 | |
| SCHEMBL4061345 | 0.83 | — | — | |
| SCHEMBL5185591 | 0.80 | APP (0.55) | APPMAPTGRM5KCNH2CA12 | |
| SCHEMBL2188047 | 0.80 | HDAC8 (0.31) | — | |
| SCHEMBL2763053 | 0.80 | RARB (0.37) | APPMAPTGRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090030248-A1 | Ethynylphenylbiadamantane derivatives | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2009-01-29 | — | — | US | disclosed |
| EP-2014636-A1 | Ethynylphenylbiadamantane derivatives | Daicel Chemical Industries, Ltd. (JP) | 2009-01-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030248-A1 | Ethynylphenylbiadamantane derivatives | CHRNA5, CHRNE, ADRA1D | APP 2669/4885MAPT 3069/4885GRM5 224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.